HER2 Positive Breast Cancers Clinical Trial Using ONT-380 and T-DM1

- The folks at Oncothyreon Inc. are studying the effects of ONT-380; T-DM1 on HER2 Positive Breast Cancers in individuals ages 18 years and older. This clinical trial is slated to start February 2014 and is expected to end circa August 2015.

Overall Study Contact Info
StatusName Contact Phone
Recruiting

This study is officially titled, "A Phase 1b, Open-label Study to Assess the Safety and Tolerability of ONT-380 Combined With T-DM1."

Locations

Northwest Medical Specialties

Tacoma, Washington - Not yet recruiting

MD Anderson

Houston, Texas - Not yet recruiting

Sarah Cannon Research Institute

Nashville, Tennessee - Recruiting

Providence Cancer Center

Portland, Oregon - Not yet recruiting

Dana Farber Cancer Institute

Boston, Massachusetts - Recruiting

University of Kansas

Kansas City, Kansas - Not yet recruiting

University of Colorado Cancer Center

Aurora, Colorado - Recruiting

University of Alabama

Birmingham, Alabama - Not yet recruiting

For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.